Field of the invention The present invention relates to S1P1/EDG1 receptor agonists of Formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing a compound of the Formula (I), and their use as compounds improving vascular function and as immunomodulating agents, either alone or in combination with other active compounds or therapies. Background of the invention The human immune system is designed to defend the body against foreign micro-organisms and substances that cause infection or disease. Complex regulatory mechanisms ensure that the immune response is targeted against the intruding substance or organism and not against the host. In some cases, these control mechanisms are unregulated and autoimmune responses can develop. A consequence of the uncontrolled inflammatory response is severe organ, cell, tissue or joint damage. With current treatment, the whole immune system is usually suppressed and the body's ability to react to infections is also severely compromised. Typical drugs in this class include azathioprine, chlorambucil, cyclophosphamide, cyclosporin, or methotrexate. Corticosteroids which reduce inflammation and suppress the immune response, may cause side effects when used in long term treatment. Nonsteroidal anti-infammatory drugs (NSAIDs) can reduce pain and inflammation, however, they exhibit considerable side effects. Alternative treatments include agents that activate or block cytokine signaling. Orally active compounds with immunomodulating properties, without compromising immune responses and with reduced side effects would significantly improve current treatments of uncontrolled inflammatory disease. In the field of organ transplantation the host immune response must be suppressed to prevent organ rejectlon. Organ transplant recipients can experience some rejection even when they are taking immunosuppressive drugs. Rejection occurs most frequently in the first few weeks after transplantation, but rejection episodes can also happen months or even years after transplantation. Combinations of up to three or four medications are commonly used to give maximum protection against rejection while minimizing side effects. Current Standard drugs used to treat the rejection of transplanted organs interfere with discrete intracellular pathways in the activation of T-type or B-type white blood cells. Examples of such drugs are cyclosporin, daclizumab, basiliximab, everolimus, or FK506, which interfere with cytokine release or signaling; azathioprine or leflunomide, which inhibit nucleotide synthesis; or 15-deoxyspergualin, an inhibitor of leukocyte differentiation. The beneficial effects of broad immunosuppressive therapies relate to their effects; however, the generalized immunosuppression which these drugs produce diminishes the immune system's defense against infection and malignancies. Furthermore, Standard immunosuppressive drugs are often used at high dosages and can cause or accelerate organ damage. Description of the invention The present invention provides novel compounds of Formula (I) that are agonists for the G protein-coupled receptor S1P1/EDG1 and have a powerful and long-lasting immunomodulating effect which is achieved by reducing the number of circulating and infiltrating T- and B-lymphocytes, without affecting their maturation, memory, or expansion. The reduction of circulating T- / B-lymphocytes as a result of S1P1/EDG1 agonism, possibly in combination with the observed improvement of endothelial cell layer function associated with S1P1/EDG1 activation, makes such compounds useful to treat uncontrolled inflammatory disease and to improve vascular functionality. The compounds of the present invention can be utilized alone or in combination with Standard drugs inhibiting T-cell activation, to provide a new immunomodulating therapy with a reduced propensity for infections when compared to Standard immunosuppressive therapy. Furthermore, the compounds of the present invention can be used in combination with reduced dosages of traditional immunosuppressant therapies, to provide on the one hand effective immunomodulating activity, while on the other hand reducing end organ damage associated with higher doses of Standard Immunosuppressive drugs. The observation of improved endothelial cell layer function associated with S1P1/EDG1 activation provides additional benefits of compounds to improve vascular function. The nucleotide sequence and the amino acid sequence for the human S1P1/EDG1 receptor are known in the art and are published in e.g.: HIa, T., and Maciag, T. J. Biol Chem. 265 (1990), 9308-9313; WO 91/15583 published 17 October 1991; WO 99/46277 published 16 September 1999. The potency and efficacy of the compounds of Formula (!) are assessed using a GTPyS assay to determine EC50 values and by measuring the circulating lymphocytes in the rat after oral administration, respectively (see in Examples). R1a represents C1-5-alkyl, C3-5-cycloalkyl, or 2-hydroxyethyl; R1b represents hydrogen or C1-3-alkyl; r R1a' and R1b, together with the nitrogen to which they are attached, form an azetidine, a pyrrolidine, a piperidine, or a morpholine ring; R2 represents hydrogen or C1.2-alkyl; R3 represents hydrogen or C1.2-alkyl; R4 represents hydrogen, C1-2-alkyl, methoxy, or halogen; R5 represents hydrogen, C1-4-alkyl, or C1-4-alkoxy; R6 represents hydroxy-C1-4-alkyl, di-(hydroxy-C1-4-alkyl)-C1-4-alkyl, 2,3-dihydroxypropyl, -CH2-(CH2)n-NRR-CH2-(CH2)n-NHCOR -CH2-(CH2)n-NHS02R -CH2-CH2-COOH, -CH2-CH2-CONRR 1-(3-carboxy-azetidinyl)-3-propionyl, 1-(2-carboxy-pyrrolidinyl)-3-propionyl, 1-(3-carboxy-pyrrolidinyl)-3-propionyl, -CH2-CH(OH)-CH2-NRR -CH2-CH(OH)-CH2-NHCOR, -CH2-CH(OH)-CH2-NHS02R -CO-NHRhydroxy, hydroxy-C2-4-alkoxy, di-(hydroxy-Ci. 4-alkyl)-Ci-4-alkoxy, 2,3-dihydroxypropoxy, 2-hydroxy-3-methoxy-propoxy, -OCH2-(CH2)m-NRR2 -OCH2-(CH2)m-NHCOR, -OCH2-(CH2)m-NHS02R2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-2-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid)-1-yl]-ethoxy, -OCH2-CH(OH)-CH2-NRR -OCH2-CH(0H)-CH2-NHC0R, -OCH2-CH(OH)-CH2-NHS02R 3-[(azetidine-3-carboxylic acid)-1 -yl]-2-hydroxypropoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid)-1 -yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid)-1-yl]-propoxy, -NRR, -NHCO-R^, or-S02NH-R Rrepresents hydrogen, methyl, ethyl, 2-hydroxyethyl, 2-hydroxy-1-hydroxymethyl-ethyl, 2,3-dihydroxy-propyl, 2-C1-2-alkoxyethyl, 3-hydroxypropyl, 2- aminoethyl, 2-(C1-4-alkylamino)ethyl, 2-(di-(C1-4-alkyl)amino)ethyl, carboxymethyl, (C1-4-alkylcarboxy)methyl, 2-carboxyethyl, or 2-(C1-4-alkylcarboxy)ethyl; R62 represents hydrogen or methyl; R63 represents methyl, ethyl, methylamino, ethylamino, or dimethylamino; R64 represents hydroxymethyl, 2-hydroxyethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, 2-amlnoethyl, or 2-methylamlno-ethyl; m represents the integer 1 or 2; n represents O, 1, or 2; and R7 represents hydrogen, Ci.2-alkyl, or halogen. The general terms used hereinbefore and hereinafter preferably have, within this disclosure, the following meanings, unless othenwise indicated: The term "Cx-y-alkyl" (x and y each being an integer) refers to a saturated straight or branched hydrocarbon chain with x to y carbon atoms. For example, a Ci.5-alkyl group contains from one to five carbon atoms. Representative examples of C1-5-alkyl groups include methyl, ethyl, /i-propyl, /so-propyl, n-butyl, /so-butyl, sec-butyl, tert-butyl, n-pentyl, /so-pentyl, 3-pentyl, and 2,2,2-trimethylethyl. Preferred examples of C1-5-alkyl groups are methyl, ethyl, /7-propyl, /so-propyl, n-butyl, /so-butyl, and 3-pentyl. Preferred examples of C1-4-alkyl groups are methyl, ethyl, n-propyl, /so-propyl, n-butyl, and /so-butyl. Preferred examples of C1-3-alkyl groups are methyl and ethyl. The term "Cx-y-alkoxy" (x and y each being an integer) refers to an alkyl-0- group wherein the alkyl group refers to a straight or branched hydrocarbon chain with x to y carbon atoms. For example, a C1-4-alkoxy group contains from one to four carbon atoms and includes methoxy, ethoxy, n-propoxy, /so-propoxy, n-butoxy, /so-butoxy, sec-butoxy, and tert-butoxy. Preferred examples of C2-4-alkoxy groups are ethoxy, n-propoxy, and /so-propoxy. The term "Cx-y-cycloalkyl" (x and y each being an integer) refers to a saturated cyclic hydrocarbon ring system with x to y carbon ring atoms. For example, a C3-5-cycloalkyl group contains from three to five carbon ring atoms and thus includes cyclopropyl, cyclobutyl, and cyclopentyl. Anaiogously, "Ca-^-cycioalkyl" includes cyclopropyl and cyclobutyl. The term "halogen" means fluoro, chloro, bromo or iodo (preferably fluoro or chloro; especially preferred chloro). ii) A particular embodiment of the invention relates to thiophene derivatives according to embodiment i), wherein A represents iii) Another particular embodiment of the invention relates to thiophene derivatives according to embodiment i), wherein A represents iv) Another particular embodiment of the invention relates to thiophene derivatives according to embodiment i), wherein A represents v) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to iv), wherein R^" represents C4-5-alkyl. vi) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to iv), wherein R^ represents C1-4alkyl, C3-4-cycloalkyl, or 2-hydroxyethyl, and R'"' represents C1-3-alkyl; or R^ and R'"', together with the nitrogen to which they are attached, form an azetidine or a pyrrolidine ring. vii) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to iv), wherein R''" represents Ci^-alkyl and R""* represents Ci-2-alkyl. viii) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to vii), wherein R^ represents Ci-2-alkyl. ix) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to vii), wherein R^ represents methyl. x) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to ix), wherein R^ represents hydrogen. xi) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to x), wherein R* represents methoxy, and R^ and R'' represent hydrogen. xii) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to x), wherein R* represents hydrogen, R' represents C1-3-alkyl or methoxy, and R^ represents C1-2-alkyl or chloro. xiii) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to x), wherein R* represents hydrogen, R® represents Ci.2-alkyl or methoxy, and R' represents methyl or chloro. xiv) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to x), wherein R6 represents hydrogen, R6 represents ethyl or methoxy, and R7 represents methyl or chloro. XV) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to x), wherein R4 represents hydrogen, R6 represents ethyl, and R7 represents methyl. xvi) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to xv), wherein R^ represents di- (hydroxy-Ci^-alkyl)-Ci^-alkyl, 2,3-dihydroxypropyl, -CH2-(CH2)n-NHCOR^, -CH2- (CH2)n-NHS02R^^ -CH2-CH2-COOH, -CH2-CH2-CONR^^R^^ 1-(3-carboxy- azetidinyl)-3-propionyl, 1 -(2-carboxy-pyrrolidinyl)-3-propionyl, 1 -(3-carboxy- pyrrolidinyl)-3-propionyl, -CH2-CH(OH)-CH2-NR^^ R^^ -CH2-CH(OH)-CH2-NHCOR^, -CH2-CH(OH)-CH2-NHS02R^^ -CO-NHR^\ hydroxy-C2^-alkoxy, di-(hydroxy-Ci^-alkyl)-Ci^-alkoxy, 2,3-dihydroxypropoxy, 2-hydroxy-3-methoxy-propoxy, -OCH2-(CH2)m-NR^^R^^ -OCH2-(CH2)m-NHCOR^, -OCH2-(CH2)m-NHS02R^^ 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-I(pyrrolidine-2-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid)-1-yl]-ethoxy, -OCH2-CH(OH)-CH2-NR^^R^^ -OCH2-CH(0H)-CH2-NHC0R^, -OCH2-CH(OH)-CH2-NHS02R^^ 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxypropoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid)-1-yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid)-1-yl]-propoxy, or-NR^^R^^. xvii) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to xv), wherein R^ represents -CH2-CH2-COOH, -CH2-CH2-CONR^^R^^ 1-(3-carboxy-azetidinyl)-3-propionyl, 1-(2-carboxy-pyrrolidinyl)-3-propionyl, 1 -{3-carboxy-pyrrolidinyl)-3-propionyl, hydroxy, hydroxy-C2-4-alkoxy, di-(hydroxy-Ci-4-alkyl)-Ciwi-alkoxy, 2,3-dihydroxypropoxy, -OCH2-(CH2)m-NR®^R^^ -OCH2-(CH2)m-NHCOR^, -OCH2-(CH2)m-NHS02R®^ 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-2-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid)-1-yl]-ethoxy, -OCH2-CH(OH)-CH2-NR^^R^^ -OCH2-CH(OH)-CH2-NHCOR^, -OCH2-CH(OH)-CH2-NHS02R^^ 3-[(azetidine-3- carboxylic acid)-1-yl]-2-hydroxypropoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid)-1-yl]-propoxy, or 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid)-1-yl]-propoxy. xviii) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to xv), wherein R^ represents -CH2-CH2-CONR^^R^^, hydroxy, hydroxy-C2^-alkoxy, di-(hydroxy-Ci^-alkyl)-Ci^-alkoxy, 2,3-dihydroxypropoxy, -OCH2-(CH2)m-NR®^R^^ -OCH2-(CH2)m-NHCOR^^ -OCH2-(CH2)m-NHS02R^^ -OCH2-CH(OH)-CH2-NR^^R^^ -OCH2-CH(0H)-CH2-NHC0R^, or -OCH2-CH(OH)-CH2-NHS02R^^ xix) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to xv), wherein R® represents di-(hydroxy-Ci-4-alkyl)-Ci^-alkoxy, 2,3-dihydroxypropoxy, -OCH2-(CH2)m-NR^^ R^^, -OCH2-(CH2)m-NHCOR^, -OCH2-CH(OH)-CH2-NR^^R®^ or -OCH2-CH(OH)-CH2-NHCOR^. xx) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to xv), wherein R® represents di-(hydroxy-Ci^-alkyl)-Ci^-alkoxy, 2,3-dihydroxypropoxy, -OCH2-CH(OH)-CH2-NR^^R^^ or -OCH2-CH(OH)-CH2-NHCOR^. xxi) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to xv), wherein R® represents 2,3-dihydroxypropoxy or -OCH2-CH(OH)-CH2-NHCOR^'*. xxii) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to xv), wherein R^ represents hydroxy-Ci^-alkyl, 2,3-dihydroxypropyl, -CH2-(CH2)n-NR^^R^^ -CH2-(CH2)n-NHCOR^^ -CH2-(CH2)n-NHS02R^^ -CH2-CH2-COOH, -CH2-CH2-CONR^^R^^ 1-(3-carboxy-azetidinyl)-3-propionyl, 1 -(2-carboxy-pyrrolidinyl)-3-propionyl, 1 -(3-carboxy-pyrrolidinyl)-3-propionyl, -CH2-CH(OH)-CH2-NR^^R^^ -CH2-CH(OH)-CH2-NHCOR^^ -CH2-CH(OH)-CH2-NHS02R^^ -CO-NHR^\ hydroxy, hydroxy-C2^-alkoxy, 2,3-dihydroxypropoxy, -OCH2-(CH2)m-NR^^R^^ -OCH2-CH(OH)-CH2-NR^^R^^ -OCH2- 10 CH(0H)-CH2-NHC0R^, 3-[(azeticiine-3-carboxylic acicl)-1-yl]-2-hydroxypropoxy, 2-hyclroxy-3-[(pyrrolidine-2-carboxylic acid)-1 -yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylicacid)-1-yl]-propoxy, -NR61R62 -NHCO-R64 or-S02NH-R61 xxiii) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to xviii), and xxii), wherein R^ represents methyl or methylamino. xxiv) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to xx), xxii), and xxiii), wherein R61 represents methyl, 2-hydroxyethyl, carboxymethyl, or 2-carboxyethyl. xxv) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to xx), and xxii) to xxiv), wherein R^^ represents hydrogen. xxvi) Another particular embodiment of the invention relates to thiophene derivatives according to any one of the embodiments i) to xxv), wherein R^ represents hydroxymethyl or 2-hydroxyethyl. xxvii) A further embodiment of the invention relates to thiophene derivatives according to embodiment i), wherein A represents R1a represents C1-5-alkyl or 2-hydroxyethyl; R1b represents hydrogen or C1-3-alkyl; or R"*' and R""*, together with the nitrogen to which they are attached, form an azetidine, a pyrrolidine, a piperidine, or a morpholine ring; R2 represents hydrogen or C1-2-alkyl; R3 represents hydrogen or C1-2-alkyl; R4 represents hydrogen; R5 represents C1-4-alkyl; R6 represents hydroxy-C1-4-alkyl, -CH2-CH2-COOH, hydroxy, 2,3-dihydroxypropoxy, or -OCH2-CH(OH)-CH2-NHCOR^; R" represents hydroxymethyl; and R7 represents C1-2-alkyl. The compounds of Formula (I) may contain one or more stereogenic or asymmetrie centers, such as one or more asymmetric carbon atoms. The compounds of Formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art. Where the plural form is used for compounds, salts, pharmaceutieal compositions, diseases and the like, this is intended to mean also a single compound, salt, or the like. Any reference hereinbefore or hereinafter to a compound of Formula (I) is to be understood as referring also to salts, espeeially pharmaeeutically aeceptable salts, of a compound of Formula (I), as appropriate and expediënt. Salts are preferably the pharmaceutically acceptable salts of the compounds of Formula (I). The term "pharmaceutically aeceptable salts" refers to non-toxic, inorganie or organic acid and/or base addition salts. Reference can be made to "Salt seleetion for basic drugs", Int. J. Pharm. (1986), 33, 201-217. Examples of preferred compounds are selected from the group consisting of: N-(3-{4-[5-(5-dimethylaminomethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6- dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-aeetamide; 3-[2,6-dimethyl-4-(5-{4-methyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2- yl}-[1,2,4]oxadiazol-3-yl)-phenoxy]-propane-1,2-diol; N-(3-{2,6-climethyl-4-[5-(4-methyl-5-methylaminomethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; 2-hydroxy-N-[2-hydroxy-3-(4-{5-[5-(isopropylamino-methyl)-4-methyl-thiophen-2-yl]-[1,2,4]oxadiazol-3-yl}-2,6-dimethyl-phenoxy)-propyl]-acetamide; N-(3-{4-[5-(5-dimethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-{3-[2,6-dimethyl-4-(5-{4-methyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; 2-hydroxy-N-(2-hydroxy-3-{4-[5-(5-{[(2-hydroxy-ethyl)-methyl-amino]-methyl}-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propyl)-acetamide; N-(3-{4-[5-(5-{[ethyl-(2-hydroxy-ethyl)-amino]-methyl}-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-(3-{2,6-dimethyl-4-[5-(4-methyl-5-pyrrolidin-1-ylmethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-(3-{2,6-dimethyl-4-[5-(4-methyl-5-piperidin-1-ylmethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; 3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenyl}-propionicacid; N-((S)-3-{4-[5-(5-dimethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-4-(5-{5-[(ethyl-methyl-amino)-methyl]-4-methyl-thiophen-2-ylH1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-6-methyl-4-(5-{4-methyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[4-(5-{5-[(butyl-methyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2-ethyl-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-4-(5-{5-[(isobutyl-methyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-4-(5-{5-[(ethyl-propyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-4-(5-{5-[(ethyl-isopropyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[4-(5-{5-[(butyl-ethyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2-ethyl-6-nnethyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; 3-[4-(5-{5-[(butyl-methyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2-ethyl-6-methyl-phenyl]-propionic acid; and 3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenyl}-propionicacid. Examples of preferred compounds are further selected from the group consisting of: N-((S)-3-{4-[5-(5-dimethylaminomethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((R)-3-{4-[5-(5-dimethylaminomethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; (S)-3-[2,6-dimethyl-4-(5-{4-methyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-phenoxy]-propane-1,2-diol; (R)-3-[2,6-dimethyl-4-(5-{4-methyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-phenoxy]-propane-1,2-diol; N-((S)-3-{2,6-dimethyl-4-[5-(4-methyl-5-methylaminonnethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((R)-3-{2,6-dimethyl-4-[5-(4-methyl-5-methylaminomethyl-thiophen-2-yl)-[1,2,4]oxacliazol-3-yl]-phenoxy}-2-hyclroxy-propyl)-2-hyclroxy-acetamicle; 2-hydroxy-N-[(S)-2-hydroxy-3-(4-{5-[5-(isopropylamino-methyl)-4-methyl-thiophen-2-yl]-[1,2,4]oxadiazol-3-yl}-2,6-dimethyl-phenoxy)-propyl]-acetamide; 2-hydroxy-N-[(R)-2-hydroxy-3-(4-{5-[5-(isopropylamino-methyl)-4-methyl-thiophen-2-yl]-[1,2,4]oxadiazol-3-yl}-2,6-dinnethyl-phenoxy)-propyl]-acetamide; N-((S)-3-{4-[5-(5-dimethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamjde; N-((R)-3-{4-[5-(5-dimethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamjde; N-{(S)-3-[2,6-dimethyl-4-(5-{4-methyl-5-[(nnethyl-propyl-amino)-nnethyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(R)-3-[2,6-dimethyl-4-(5-{4-methyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; 2-hydroxy-N-((S)-2-hydroxy-3-{4-[5-(5-{[(2-hydroxy-ethyl)-methyl-amino]-methyl}-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propyl)-acetamide; 2-hydroxy-N-((R)-2-hydroxy-3-{4-[5-(5-{[(2-hydroxy-ethyl)-methyl-annino]-methyl}-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propyl)-acetamide; N-((S)-3-{4-[5-(5-{[ethyl-(2-hydroxy-ethyl)-amino]-methyl}-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((R)-3-{4-[5-(5-{[ethyl-(2-hydroxy-ethyl)-amino]-methyl}-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{2,6-dimethyl-4-[5-(4-methyl-5-pyrrolidin-1-ylmethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((R)-3-{2,6-dimethyl-4-[5-(4-methyl-5-pyrrolidin-1-ylmethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{2,6-dimethyl-4-[5-(4-methyl-5-piperidin-1-ylmethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((R)-3-{2,6-dimethyl-4-[5-(4-methyl-5-piperidin-1-ylmethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; 3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenyl}-propionicacid; N-((S)-3-{4-[5-(5-dimethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-4-(5-{5-[(ethyl-methyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-6-methyl-4-(5-{4-methyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[4-(5-{5-[(butyl-methyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2-ethyl-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamjde; N-{(S)-3-[2-ethyl-4-(5-{5-[(isobutyl-methyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-4-(5-{5-[(ethyl-propyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-4-(5-{5-[(ethyl-isopropyl-amino)-methyl]-4-methyl-thiophen-2-ylH1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[4-(5-{5-[(butyl-ethyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2-ethyl-6-methyl-phenoxy]-2-hyclroxy-propyl}-2-hyclroxy-acetamide; 3-[4-(5-{5-[(butyl-methyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2-ethyl-6-methyl-phenyl]-propionic acid; and 3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenyl}-propionicacid. Examples of preferred compounds are further selected from the group consisting of: (R)-3-{4-[5-(5-dimethylaminomethyl-4-ethyl-thiophen-2-yl)-[1,2,4]oxadia2ol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol; (R)-3-[2-ethyl-4-(5-{4-ethyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-propane-1,2-diol; N-((S)-3-{4-[5-(5-dimethylaminomethyl-4-ethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-4-(5-{4-ethyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; 3-{4-[5-(5-dinnethylaminomethyl-4-ethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenyl}-propionic acid; 3-[2-ethyl-4-(5-{4-ethyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenyl]-propionic acid; N-((S)-3-{4-[5-(5-dimethylaminometiiyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-{(S)-3-[4-(5-{5-[(butyl-methyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2,6-dimethyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; 2-liydroxy-N-{(S)-2-liydroxy-3-[4-(5-{5-[(isobutyl-methyl-amino)-metliyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2,6-dimethyl-phenoxy]-propyl}-acetamide; N-{(S)-3-[4-(5-{5-[(ethyl-propyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2,6-dimethyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[4-(5-{5-[(ethyl-isopropyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2,6-dimethyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-4-(5-{5-[(ethyl-isobutyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; (3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenyl}-propionylamino)-aceticacid; {3-[2-ethyl-4-(5-{5-[(ethyl-propyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenyl]-propionylamino}-aceticacid; 3-{3-[2-ethyl-6-methyl-4-(5-{4-methyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-ylH1,2,4]oxadiazol-3-yl)-phenyl]-propionylamino}-propionicacid; 3-(3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenyl}-propionylamino)-propionicacid; 3-{3-[2-ethyl-4-(5-{5-[(ethyl-propyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenyl]-propionylamino}-propionicacid; N-((S)-3-{4-[3-(5-dimethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-5-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{4-[3-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-5-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{4-[5-(5-dimethylaminomethyl-4-methyl-thiophen-2-yl)-[1,3,4]oxadiazol-2-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-methoxy-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{2-chloro-4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-3-methyl-phenoxy}-2-hyclroxy-propyl)-2-hyclroxy-acetamicle; (S)-3-{2-chloro-4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol; (S)-1-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-3-(2-hydroxy-ethylamino)-propan-2-ol; 3-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-propan-1-ol; 3-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-propane-1,2-diol; 2-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-propane-1,3-diol; (S)-1-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-3-(2-methoxy-ethylamino)-propan-2-ol; (S)-1-(2-amino-ethylamino)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propan-2-ol; ((S)-3-{4-[5-{5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-aceticacid; [((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-methyl-amino]-aceticacid; 3-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-propionic acid; N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-3-hydroxy-propionamide; 2-amino-N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-acetamide; N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxacliazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-methylamino-acetamide; 3-amino-N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-propionamide; and N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-3-methylamino-propionamide. The compounds of Formula (I) and their pharmaceutically acceptable salts, can be used as a medicament, e.g. in the form of pharmaceutical compositions for enteral or parenteral administration, and are suitable for decreasing the number of circulating lymphocytes and for the prevention and/or treatment of diseases or disorders associated with an activated immune system. The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilied in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing" [published by Lippincott Williams & Wilkins]) by bringing the described compounds of Formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, pharmaceutically acceptable solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants. Such diseases or disorders associated with an activated immune system and to be prevented/treated with the compounds of Formula (I) are for example selected from the group consisting of rejection of transplanted organs, tissue or cells; graft-versus-host diseases brought about by transplantation; autoimmune syndromes including rheumatoid arthritis; systemic lupus erythematosus; antiphospholipid syndrome; Hashimoto's thyroiditis; lymphocytic thyroiditis; multiple sclerosis; myasthenia gravis; type I diabetes; uveitis; episcleritis; scleritis; Kawasaki's disease, uveo-retinitis; posterior uveitis; uveitis associated with Behcet's disease; uveomeningitis syndrome; allergic encephalomyelitis; chronic allograft vasculopathy; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritls; inflammatory and hyperproliferative skin diseases; psoriasis; psoriatic arthritis; atopic dermatitis; myopathy; myositis; osteomyelitis; contact dermatitis; eczematous dermatitis; seborrhoeic dermatitis; lichen planus; pemphigus; bullous pemphigoid; epidermolysis bullosa; urticaria; angioedema; vasculitis; erythema; cutaneous eosinophilia; acne; scleroderma; alopecia areata; keratoconjunctivitis; vernal conjunctivitis; keratitis; herpetic keratitis; dystrophia epithelialis corneae; corneal leukoma; ocular pemphigus; Mooren's ulcer; ulcerative keratitis; scleritis; Graves' ophthalmopathy; Vogt-Koyanagi-Harada syndrome; sarcoidosis; pollen allergies; reversible obstructive ainA/ay disease; bronchial asthma; allergic asthma; intrinsic asthma; extrinsic asthma; dust asthma; chronic or inveterate asthma; late asthma and airway hyper-responsiveness; bronchiolitis; bronchitis; endometriosis; orchitis; gastric ulcers; ischemic bowel diseases; inflammatory bowel diseases; necrotizing enterocolitis; intestinal lesions associated with thermal burns; coeliac disease; proctitis; eosinophilic gastroenteritis; mastocytosis; Crohn's disease; ulcerative colitis; vascuiar damage caused by ischemic diseases and thrombosis; atherosclerosis; fatty heart; myocarditis; cardiac infarction; aortitis syndrome; cachexia due to viral disease; vascuiar thrombosis; migraine; rhinitis; eczema; interstitial nephritis; IgA-induced nephropathy; Goodpasture's syndrome; hemolytic-uremic syndrome; diabetic nephropathy; glomerulosclerosis; glomerulonephritis; tubulointerstitial nephritis; interstitial cystitis; multiple myositis; Guillain-Barré syndrome; Meniere's disease; polyneuritis; multiple neuritis; myelitis; mononeuritis; radiculopathy; hyperthyroidism; Basedow's disease; thyrotoxicosis; pure red cell aplasia; aplastic anemia; hypoplastic anemia; idiopathic thrombocytopenic purpura; autoimmune hemolytic anemia; autoimmune thrombocytopenia; agranulocytosis; pernicious anemia; megaloblastic anemia; anerythroplasia; osteoporosis; fibroid lung; idiopathic interstitial pneumonia; dermatomyositis; leukoderma vulgaris; ichthyosis vulgaris; photoallergic sensitivity; cutaneous T cell lymphoma; polyarteritis nodosa; Huntington's chorea; Sydenham's chorea; myocardosis; myocarditis; scleroderma; Wegener's granuloma; Sjogren's syndrome; adiposis; eosinophilic fascitis; lesions of gingiva, periodontium, alveolar bone, substantia ossea dentis; male pattern alopecia or alopecia senilis; muscular dystrophy; pyoderma; Sezary's syndrome; hypophysitis; chronic adrenal insufficiency; Addison's disease; ischemia-reperfusion injury of organs which occurs upon preservation; endotoxin shock; pseudomembranous colitis; colitis caused by drug or radiation; ischemic acute renal insufficiency; chronic renal insufficiency; lung cancer; malignancy of lymphoid origin; acute or chronic lymphocytic leukemias; lymphoma; pulmonary emphysema; cataracta; siderosis; retinitis pigmentosa; senile macular degeneration; vitreal scarring; corneal alkali burn; dermatitis erythema; ballous dermatitis; cement dermatitis; gingivitis; periodontitis; sepsis; pancreatitis; peripheral artery disease; carcinogenesis; solid cancer tumors; metastasis of carcinoma; hypobaropathy; autoimmune hepatitis; primary biliary cirrhosis; sclerosing cholangitis; partial liver resection; acute liver necrosis; cirrhosis; alcoholic cirrhosis; hepatic failure; fulminant hepatic failure; late-onset hepatic failure; and "acute-on-chronic" liver failure. Preferred diseases or disorders to be treated and/or prevented with the compounds of Formula (!) are selected from the group consisting of rejection of transplanted organs such as kidney, liver, heart, lung, pancreas, cornea, and skin; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes including rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, thyroiditis such as Hashimoto's thyroiditis, uveo-retinitis; atopic diseases such as rhinitis, conjunctivitis, dermatitis; asthma; type I diabetes; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; solid cancers and tumor metastasis. Particularly preferred diseases or disorders to be treated and/or prevented with the compounds of Formula (!) are selected from the group consisting of rejection of transplanted organs selected from kidney, liver, heart and lung; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes selected from rheumatoid arthritis, multiple sclerosis, psoriasis, psoriatic arthritis, Crohn's disease, and Hashimoto's thyroiditis; and atopic dermatitis. Very preferably tlie diseases or disorders to be treated and/or prevented with the compounds of Formula (I) are selected from multiple sclerosis and psoriasis The present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of Formula (I). Furthermore, compounds of the Formula (!) are also useful, in combination with one or several immunomodulating agents, for the prevention and/or treatment of the diseases and disorders mentioned herein. According to a preferred embodiment of the invention, said agents are selected from the group consisting of immunosuppressants, corticosteroids, NSAID's, cytotoxic drugs, adhesion molecule inhibitors, cytokines, cytokine inhibitors, cytokine receptor antagonists and recombinant cytokine receptors. The present invention also relates to the use of a compound of Formula (!) for the preparation of a pharmaceutical composition, optionally for use in combination with one or several immunomodulating agents, for the prevention or treatment of the diseases and disorders mentioned herein. The compounds of Formula (I) can be manufactured by the methods given below, by the methods given in the Examples or by analogous methods. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures. Compounds of the Formula (!) of the present invention can be prepared according to the general sequence of reactions outlined below. Only a few of the synthetic possibilities leading to compounds of Formula (I) are described. 23 Compounds of the Formula (I) may be prepared by reacting a compound of Structure 1 with a compound of Structure 2 in the presence of a reducing agent such as NaBH4, NaCNBH3, NaBH(CH3COO)3, LiBH4, etc. in a solvent such as methanol, acetonitrile, 1,2-dichloroethane, dichloromethan, NMP, THF, etc, or mixtures thereof, at temperatures between room temperature and the boiling point of the corresponding solvent (Lit.: e.g. D. H. Boschelli et al., J. Med. Chem. 48 (2005) 3891-3902; Abdel-Magid, A. F., J. Org. Chem. 61 (1996), 3849-3862). Alternatively, the above mentioned reductive amination step may also be performed using a compound of Structure 1 and a primary amine R1a-NH2 or R1b-NH2; The second substitutent R1b or R1a may then be introduced by a subsequent alkylation reaction using a compound R1b-X and R1a-X, respectively, wherein X represents a reactive group such as a halogen atom e.g. chlorine, bromine or iodine. Such an alkylation reaction may be carried out in a solvent such as THF, dioxane, DMF or mixtures thereof, in the presence of a base such as NaH, LiH, LiHMDS, etc. The nature of the substituent R^ influences the choice between the one-step reductive amination or the two step reductive amination - alkylation procedure. Compounds of Structure 1 which represent a 5-thiophen-2-yl-[1,2,4]oxadiazole derivative, are prepared by reacting a compound of Structure 3 in a solvent such as xylene, toluene, benzene, pyridine, DMF, dichloromethane, acetic acid, trifluoroacetic acid, etc. at rt or elevated temperatures in the presence or absence of auxiliaries such as acids (e.g. TFA, acetic acid, HCI, etc), bases (e.g. NaH, NaOAc, NaaCOa, K2CO3, trietliylamine, etc), tetraalkylammonium salts, or water removing agents (e.g. oxalyl cliloride, a carboxylic acid anhydride, POCI3, PCI5, P4O10, molecular sieves, etc.) (Lit.: e.g. A. R. Gangloff, J. Litvalc, E. J. Siielton, D. Sperandio, V. R. Wang, K. D. Rice, Tetrahedron Lett. 42 (2001), 1441-1443; T. SuzulDiethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]- phenyl}-ethanol The title compound (267 mg) is obtained as a yellow oil following Method A and starting from N-hydroxy-4-(2-hydroxy-ethyl)-benzamidine (1.25 g, 6.93 mmol) and 5-diethylaminomethyi-4-methyl-thiophene-2-carboxylic acid (1.50 g, 6.60 mmol); LC-MS: tR = 0.52 min; [M+lf = 372.11; ""H NMR (CDCI3): {t.J = 7.0 Hz, 6 H), 2.25 (s, 3 H), 2.56-2.69 (m, 4 H), 2.96 (t, J = 6.5 Hz, 2 H), 3.72 (s, 2 H), 3.93 (t, J = 6.5 Hz, 2 H), 7.37 (d, J = 7.8 Hz, 2 H), 7.66 (s, 1 H), 8.09 (d, J = 7.5 Hz, 2 H). Example 160 2-{4-[5-(5-Diethylaminoniethyl-4-methyl-thiophen-2-yi)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethylamine a) To a cooled (0°C) solution of 2-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2- yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethanol (196 mg, 488 μmol) and DIPEA (84 mg, 732 μmol) in THF (5 mL), methanesulfonyl chloride (126 mg, 976 μmol) is added as a solution in THF (2.5 mL). The reaction mixture is stirred at 0°C for 1 h, then at rt for 1 h. The mixture is diluted with DCM (100 mL) and washed with brine (3x50 mL). The organic extract is dried over MgS04, filtered, concetrated and dried to give crude methanesulfonic acid 2-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)- [1,2,4]oxadiazol-3-yl]-phenyl}-ethyl ester (295 mg); LC-MS: \R = 0.59 min; [M+1]* = 449.71. b) A solution of methanesulfonic acid 2-{4-[5-(5-diethylaminomethyl-4-methyl- thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethyl ester (295 mg, 658 ^mol) in 7 N NH3 in methanol (10 mL) is stirred in a sealed vessel at 80°C for 16 h. The reaction mixture is concentrated and dried to give the title compound (255 mg) as a pale yellow oil; LC-MS: tR = 0.64 min; [M+1] = 370.97. Example 161 (2-{4-[5-(5-DiethylaminomethyM-inethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]- phenyl}-ethyl)-methyl-amine The title compound (3 mg) is obained as a pale yellow solid in analogy to Example 160 starting from methanesulfonic acid 2-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethyl ester (50 mg, 111 |u,mol) and 2 M methylamine in THF (4 mL); LC-MS: tp = 0.63 min; [M+lf = 385.03; ^H NMR (CDCI3): y 1.11 (t, J = 7.0 Hz, 6 H), 2.26 (s, 3 H), 2.53 (s, 2 H), 2.63 (q, J = 7.3 Hz, 4 H), 2.89-3.08 (m, 53 H), 3.73 (s, 2 H), 7.36 (d, J = 8.0 Hz, 2 H), 7.66 (s, 1 H), 8.09 (d, J = 8.3 Hz, 2 H). Example 162 2-(2-{4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3- yl]-phenyl}-ethylamino)-ethanol The title compound (6 mg) is prepared in analogy to Example 160 starting from methanesulfonic acid 2-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethyl ester (50 mg, 111 μmol) and ethanolamine (34 mg, 556 μmol); LC-MS: tp = 0.63 min; [M+1] = 415.07; ^H NMR (CDCI3): 11.11 (t, J = 7.0 Hz, 6 H), 2.26 (s, 3 H), 2.63 (q, J = 7.0 Hz, 4 H), 2.80-2.86 (m, 2 H), 2.87-2.93 (m, 2 H), 2.94-3.00 (m, 2 H), 3.62-3.67 (m, 2 H), 3.73 (s, 2 H), 7.35 (d, J = 8.0 Hz, 2 H), 7.67 (s, 1 H), 8.09 (d, J = 8.0 Hz, 2 H). Example 163 N-{2-{4-[5-(5-Diethylaminomethyl-4-methyi-thiophen-2-yi)-[1,2,4]oxadiazol-3- yl]-phenyl}-ethyi)-2-hydroxy-acetamide To a solution of glycolic acid (15 mg, 202 μmol) and DIPEA (35 mg, 270 nmol) in DMF (5 mL) is added HOBt (27 mg, 202 μmol) and EDC hydrochloride (39 mg, 202 μmol) at 0°C. The mixture is stirred for 15 min at OX. Then 2-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethylamine is added and stirring is continued for 1 h at 0°C. The reaction is quenched with water, diluted with sat. aq. NaHCOa and the mixture is extracted three times with EA. The combined organic extracts are dried over MgS04, fiitered and concentrated. The crude product is purified on prep. TLC plates using DCM containing 10% of 7 N NH3 in methanol to give the title compound (4 mg) as a colourless oil; LC-MS: tR = 0.69 min; [M+1]* = 429.06. Example 164 N-(2-{4-[5-(5-Diethylamlnomethyl4-methyl-thiophen-2-yi)-[1,2,4]oxadiazol-3- yl]-phenyl}-ethyl)-3-hydroxy-propionamide The title compound (3 mg) is prepared in analogy to Example 163 by coupling 2-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethylamine (50 mg, 135 μmol) with 3-hydroxypropionic acid (18 mg, 202 |j,mol); LC-MS: tp = 0.71 min; [M+l]* = 442.76. Example 165 N-(2-{4-[5-(5-Diethylaminomethyl-4-methyl-thlophen-2-yl)-[1,2,4]oxadiazol-3- yl]-phenyl}-ethyl)-2-methylamlno-acetamide [(2-{4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethylcarbamoyl)-methyl]-methyl-carbamic acid tert-butyl ester is prepared in analogy to Example 163 by coupling 2-{4-[5-(5-diethylaminometliyl-4-metliyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethylamine (20 mg, 54 ^imol) with (tert-butoxycarbonyl-methyl-amino)-acetic acid (15 mg, 81 μmol); LC-MS: IR = 0.84 min; [M+1] = 542.20; ^H NMR (CDCI3): 51.16 (m, 6 H), 1.44 (s, 9 H), 2.27 (s, 3 H), 2.88 (s, 3 H), 2.90-2.99 (m, 2 H), 3.61 (q, J = 6.5 Hz, 2 H), 3.75 (s br, 1 H), 3.85 (s, 2 H), 7.34 (d, J = 8.0 Hz, 2 H), 7.67 (s, 1 H), 8.10 (d, J = 8.0 Hz, 2 H). This material (18 mg, 30 μmol) is dissolved in DCM (2 mL) and TFA (50 μL) is added. The mixture is stirred at rt for 18 h before it is diluted with EA and waslied with sat. aq. NaHCOa solution. The organic extract is dried over Na2S04, filtered and concentrated. The crude product is purified by prep. HPLC and on prep. TLC plates with DCM containing 10% of 7 N NH3 in methanol to give the title compound (12 mg) as a colourless solid; LC-MS: tR = 0.64 min; [M+1] = 442.00. Example 166 N-{2-{4~[5-(5-Diethylaminomethyl-4-methyi-thiophen-2-yl)-[1,2,4]oxadiazol-3- yl]-phenyl}-ethyl)-methanesulfonamide The title compound (3 mg) is prepared in analogy to Example 155 starting from 2-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-ethylamine (10 mg, 27 μmol) and methanesulfonyl chloride (4 mg, 35 μmol); LC-MS: tR = 0.78 min; [M+1] = 448.99; ^H NMR (CDCI3):51.11 (t, J = 7.0 Hz, 6 H), 2.26 (s, 3 H), 2.64 (q, J = 7.3 Hz, 4 H), 2.89 (s, 3 H), 2.96-3.01 (m, 2 H), 3.49 (q, J = 6.8 Hz, 2 H), 3.73 (s, 2 H), 4.23 (t br, J = 6.3 Hz, 1 H), 7.37 (d, J = 8.0 Hz, 2 H), 7.67 (s, 1 H), 8.13 (d, J = 8.3 Hz, 2 H). Example 167 rac-3-{4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-propane-1,2-diol a) {5-[3-(4-Allyl-phenyl)-[1,2,4]oxadiazol-5-yl]-3-methyl-thiophen-2-ylmethyl}-diethyl-amine (625 mg) is obtained as a yellow oil starting from 5-diethylaminomethyl-4-methyl-thiophene-2-carboxylic acid (1.50 g, 6.60 mmol) and 4-alkyl-N-hydroxy- benzamidine (1.28 g, 7.26 mmol) according to Method A; LC-MS: IR = 0.64 min; [M+1] = 368.20. b) To a solution of {5-[3-(4-allyl-phenyl)-[1,2,4]oxadiazol-5-yl]-3-methyl-thiophen-2-ylmethyl}-diethyl-amine (550 mg, 1.50 mmol) in acetone (7.5 mL) and water (0.5 mL), OSO4 (38 mg, as a 2.5% solution in butanol) foliowed by N-methyl morpholine-N-oxide (243 mg, 1.80 mmol) is added. The mixture is stirred at rt for 16 h. The clear yellow solution is diluted with DCM, washed with water (3x50 mL), dried over MgS04, filtered, concentrated and dried to give crude title compound (619 mg) as yellow oil; LC-MS: tp = 0.48 min; [M+1] = 401.70; ^H NMR (CDCI3): ^1.11 (t, J = 7.0 Hz, 6 H), 2.25 (s, 3 H), 2.63 (q, J = 7.3 Hz, 4 H), 2.84-2.92 (m, 2 H), 3.55 (dd, J = 11.0, 7.0 Hz, 1 H), 3.69-3.76 (m, 4 H), 3.96-4.04 (m, 1 H). 7.37 (d, J = 7.8 Hz, 2 H), 7.66 (s, 1 H). 8.08 (d, J = 7.8 Hz, 2 H). Example 168 rac-1-Amino-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)- [1,2,4]oxadiazoi-3-yl]-phenyl}-propan-2-ol a) To a cooled (O^C) solution of rac-3-{4-[5-(5-diethylaminomethyl-4-methyl- thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-propane-1,2-diol (619 mg, 1.54 mmol) in THF (15 mL), DIPEA (399 mg, 3.08 mmol) foliowed by methansulfonyl chloride (247 mg, 2.16 mmol) is added. The mixture is stirred at 0°C for 1 h, then at rt for 1 h. The mixture is diluted with DCM, washed with brine (3x50 mL), dried over MgS04, filtered, concentrated and dried to give crude rac-methanesulfonic acid 3- {4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}- 2-hydroxy-propyl ester (955 mg) as a light brown oil; LC-MS: tp = 0.54 min; [M+1]* = 480.10. b) A solution of the above rac-methanesulfonic acid 3-{4-[5-(5-diethylaminomethyl- 4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-2-hydroxy-propyl ester (600 mg, 1.33 mmol) in 7 M NH3 in methanol (10 mL) is stirred in a sealed vessel at 80°C for 16 h. The mixture is diluted with EA and washed with water and brine. The organic extract is dried over MgS04, filtered and concentrated. The crude product is purified on prep. TLC plates using DCM containing 10% of methanol to give the title compound (242 mg) as a pale yellow resin; LC-MS: tR = 0.63 min; [M+1]* = 400.93. Example 169 rac-N-(3-{4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxacliazol- 3-yl]-phenyl}-2-hydroxy-propyl)-2-hydroxy-acetamide The title compound (31 mg) is prepared in analogy to Example 163 starting from rac-1-amino-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-propan-2-ol (50 mg, 125 μmol) and glycolic acid (13 mg, 175 nmol); LC-MS: tR = 0.68 min; [M+1]= 458.68. ^H NMR (CDCI3): ^1.09 (t, J = 7.0 Hz, 6 H), 2.23 (s, 3 H), 2.62 (q, J = 7.0 Hz, 4 H), 2.75-2.87 (m, 2 H), 3.18-3.28 (m, 1 H), 3.50-3.58 (m, 1 H), 3.70 (s, 2 H), 3.94-4.02 (m, 1 H), 4.06 (s, 2 H). 7.14 (t, J = 5.5 Hz, 1 H), 7.33 (d, J = 8.3 Hz, 2 H), 7.64 (s, 1 H), 8.03 (d, J = 8.0 Hz, 2 H). Example 170 rac-N-(3-{4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol- 3-yi]-phenyl}-2-hydroxy-propyl)-methanesulfonamide The title compound (12 mg) is obtained as a pale yellow oil in analogy to Example 155 starting from rac-1-amino-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-propan-2-ol (25 mg, 62 μmol) and methansulfonyl chloride (9 mg, 75 μmol); LC-MS: tR = 0.73 min; [M+1] = 479.07; H NMR (CDCI3): J1.11 (t, J = 7.0 Hz, 6 H), 2.25 (s, 3 H), 2.63 (q, J = 7.0 Hz, 4 H), 2.85 (dd, J= 13.6, 8.3 Hz, 1 H), 2.93 (dd, J = 13.8, 4.8 Hz, 1 H), 3.01 (s, 3 H), 3.10-3.18 (m, 1 H), 3.34-3.41 (m, 1 H), 3.72 (s, 2 H), 4.05-4.13 (m, 1 H), 4.84 (t, J = 6.0 Hz, 1 H), 7.36 (d, J = 8.0 Hz, 2 H), 7.67 (s, 1 H), 8.11 (d, J = 8.3 Hz, 2 H). Example 171 rac-N-(3-{4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-2-hydroxy-propyl)-sulfamlc acid dimethyl-amide The title compound (21 mg) is prepared in analogy to Example 166 starting from rac-1-amino-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenyl}-propan-2-ol (50 mg, 125 μmol) and dimethylsulfamoyl chloride (22 mg, 150 ^imol); LC-MS: tR = 0.76 min; [M+1] = 508.18; ^H NMR (CDCI3): J1.11 (t, J = 7.0 Hz, 6 H), 2.25 (s, 3 H), 2.64 (q, J = 7.0 Hz, 4 H), 2.83 (s, 6 H), 2.85-2.94 (m, 2 H), 3.03-3.10 (m, 1 H), 3.24-3.30 (m, 1 H), 3.73 (s, 2 H), 4.04-4.11 (m, 1 H), 7.37 (d, J = 8.3 Hz, 2 H), 7.66 (s, 1 H), 8.10 (d, J = 8.3 Hz, 2 H). Example172 rac-1-{4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3- yl]-phenyl}-3-(2-hydroxy-ethylamino)-propan-2-ol The title compound (16 mg) is prepared starting from rac-methanesulfonic acid 3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yi]-phenyl}-2-hydroxy-propyl ester (100 mg, 208 μmol) and ethanolamine (64 mg, 1.04 mmol) in analogy to Example 168 step b); LC-MS: tR = 0.63 min; [M+1] = 445.07; 1H NMR (CDCI3): ^1.10 (t, J = 7.0 Hz, 6 H), 2.25 (s, 3 H), 2.53 (s br, 2 H), 2.59-2.67 (m, 5 H), 2.77-2.90 (m, 5 H), 3.69 (t, J = 5.0 Hz, 2 H), 3.72 (s, 2 H), 3.95-4.03 (m, 1 H), 7.37 (d, J = 8.3 Hz, 2 H), 7.66 (s, 1 H), 8.08 (d, J = 8.0 Hz, 2 H). Example 173 4-[5-(5-Dimethylaminomethyl-4-methyl-thiophen-2-yl)-[1,3,4]thiadiazol-2-yl]-2- ethyl-6-methyl-phenol The titie compound (13 mg) is prepared staring from 5-[5-(3-ethyl-4-hydroxy-5-methyl-phenyl)-[1,3,4]thiadiazol-2-yl]-3-methyl-thiophene-2-carbaldehyde (21 mg, 61 μmol) and dimethylamine (33 mg, 244 μmol, as a 33% solution in ethanol) according to Method C; LC-MS: tR =0.56 min; [M+1]* = 374.07; 1H NMR (D6-DMSO): J1.18 (t, J = 7.3 Hz, 3 H), 2.20 (s, 3 H), 2.24 (s, 6 H), 2.26 (s, 3 H), 2.67 (q, J = 7.3 Hz, 2 H), 3.57 (s, 2 H), 7.47 (s, 1 H), 7.56 (s, 2 H). Example 174 2-{4-[5-(5-Dimethyiaminomethyl-4-methyl-th[ophen-2-yl)1,3,4]thiadiazol-2-yl]- 2-ethyl-6-methyl-phenoxy}-ethanol a) To a suspension of 5-[5-(3-ethyl-4-hydroxy-5-methyl-phenyl)-[1,3,4]thiadiazol-2-yl]-3-methyl-thiophene-2-carbaldehyde (54 mg, 157 μmol) and K2CO3 (65 mg, 470 μmol) in acetonitrile (10 mL), (2-bromoethoxy)-tert.-butyl-dimethyl silane (66 mg, 274 μmol) is added. The mixture is stirred at 70°C for 2 h before another portion of (2-bromoethoxy)-tert.-butyl-dimethyl silane (66 mg, 274 |imol) is added. Stirring is continued at 60°C for 16 h. The mixture is cooled to rt, acidified by adding 1 N aq. HCI (2 mL) and stirred at rt for 10 min. The reaction mixture is concentrated to a volumen of about 1 mL, is diluted with DMF (1.5 mL) and is then separated by prep. HPLC (XBridge Rp C18, 30x75 mm, eluting with a gradiënt of acetonitrile in water containing 0.5 % of aq. ammonia) to give 5-{5-[3-ethyl-4-(2-iiydroxy-ethoxy)-5-methyl-phenyl]-[1,3,4]thiadiazol-2-yl}-3-methyl-thiophene-2-carbaldehyde (33 mg) as a pale yellow resin; LC-MS: tp =0.69 min; [M+1] = 429.06. b) Tlie title compound (24 mg) is obtained as a colourless resin starting from tiie above 5-{5-[3-ethyl-4-(2-hydroxy-etiioxy)-5-methyl-phenyl]-[1,3,4]thiadiazol-2-yl}-3-methyl-thiophene-2-carbaldehyde (33 mg, 85 μmol) and dimethylamine (46 mg, 340 Kimoi); LC-MS*: tR =0.96 min; [M+1] = 418.01; 1H NMR (D6-DMSO): 1.22 (t, J = 7.5 Hz, 3 H), 2.20 (s, 3 H), 2.25 (s, 6 H), 2.34 (s, 3 H), 2.74 (q, J = 7.5 Hz, 2 H), 3.58 (s, 2 H), 3.72-3.77 (m, 2 H), 3.85 (t, J = 4.5 Hz, 2 H), 4.92 (t, J = 5.5 Hz, 1 H), 7.52 (s, 1 H), 7.67 (s, 2 H). The following Examples are prepared foilowing the procedure given in Example 95 foliowed by the procedure given in Example 96 starting from the appropriate 3-[2- ethyl-4-(5-{5-[(mono- or di-alkylamino)-methyl]-4-methyl-thiophen-2-yl}- [1,2,4]oxadiazol-3-yl)-6-methyl-phenyl]-propionic acid and pyrrolidine-3-carboxylic acid methyl ester. Example 177 ^H NMR (De-DMSO): ^1.05 (d, J = 6.8 Hz, 6 H), 1.22 (t, J = 7.5 Hz, 3 H), 1.92-2.15 (m, 2 H), 2.22 (s, 3 H), 2.23 (s, 3 H), 2.36-2.44 (m, 5 H), 2.67-2.76 (m, 2 H), 2.87-3.14 (m, 4 H), 3.30-3.66 (m, 6 H), 3.71 (s, 2 H), 7.69 (s, 2 H), 7.81 (s, 1 H). Example 180 ^H NIVIR (De-DMSO): SO.89 (t, J = 7.3Hz, 3 H), 1.03 (t, J = 7.0 Hz, 3 H), 1.22 (t, J = 7.5 Hz, 3 H), 1.48 (h, J = 7.5 Hz, 2 H), 1.98-2.15 (m, 2 H), 2.22 (s, 3 H), 2.36-2.42 (m, 5 H), 2.43-2.48 (m, 3 H), 2.57 (q, J = 6.8 Hz, 2 H), 2.68-2.76 (m, 2 H), 2.88-2.94 (m, 2 H), 2.98-3.14 (m, 1 H), 3.32-3.66 (m, 5 H), 3.74 (s, 2 H), 7.69 (s, 2 H), 7.81 (s, 1 H). The following Examples are prepared following the procedure given in Example 9£ foliowed by the procedure given in Example 96 starting from the appropriate 3-[2- ethyl-4-(5-{5-[(mono- or di-alkylamino)-methyl]-4-methyl-thiophen-2-yl}- [1,2,4]oxadiazol-3-yl)-6-methyl-phenyl]-propionic acid and azetidine-3-carboxyli( acid methyl ester. Example 182 ^H NMR (D6-DMSO): ^0.90 (t, J = 7.3 Hz, 3 H), 1.22 (t, J = 7.5 Hz, 3 H), 1.51 (h, J = 7.0 Hz, 2 H), 2.18-2.22 (m, 2 H), 2.23 (s, 3 H), 2.25 (s, 3 H), 2.39 (s, 3 H), 2.40-2.43 (m, 2 H), 2.72 (q, J = 7.5 Hz, 2 H), 2.84-2.90 (m, 2 H), 3.35-3.42 (m, 1 H), 3.69 (s, 2 H), 3.90 (dd, J = 9.5, 5.8 Hz, 1 H), 4.03 (t, J = 9.3 Hz, 1 H), 4.12 (dd, J = 8.5, 6.0 Hz, 1 H), 4.23 (t, J = 9.0 Hz, 1 H), 7.69 (s, 2 H), 7.82 (s, 1 H). Example 185 ^H NMR (De-DMSO): ^1.04 (t, J = 7.0 Hz, 6 H), 1.22 (t, J = 7.3 Hz, 3 H), 2.18-2.26 (m, 5 H), 2.39 (s, 3 H), 2.58 (q, J = 7.0 Hz, 4 H), 2.72 (q, J = 7.8 Hz, 2 H), 2.82-2.90 (m, 2 H), 3.36-3.43 (m, 1 H), 3.74 (s, 2 H), 3.90 (dd, J = 9.5, 6.0 Hz, 1 H), 4.03 (t, J = 9.3 Hz, 1 H), 4.12 (dd, J = 8.0, 6.0 Hz, 1 H), 4.24 (t, J = 8.8 Hz, 1 H), 7.69 (s, 2 H), 7.81 (s, 1 H). Example 187 2-Chloro-4-[5-(5-diethylaminomethyl-4-methyl-thlophen-2-yl)-[1,2,4]oxadiazol- 3-yi]-6-methyl-phenylamine The title compound (20 mg) is prepared starting from 5-diethylaminomethyl-4-methyl-thiophene-2-carboxylic acid (100 mg, 440 μmol) and 4-amino-3-chloro-N-hydroxy-5-methyl-benzamidine (97 mg, 484 )imol) according to Method A; LC-MS: tp = 0.61 min; [M+1] = 391.08; ^H NMR (CDCI3): ^1.11 (t, J= 7.0 Hz, 6 H), 2.25 (s, 3 H), 2.29 (s, 3 H), 2.57-2.70 (m, 4 H), 3.72 (s, 2 H), 7.65 (s, 1 H), 7.78 (s, 1 H), 7.98(d, J=1.5Hz, 1 H). Example 188 N-{2-Chloro-4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)- [1,2,4]oxacliazol-3-yl]-6-methyl-phenyl}-2-hyclroxy-acetamide A solution of benzyloxyacetyl chloride (142 mg, 767 μmol) in DCM (2 mL) is added to a solution of 2-chloro-4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenylamine (30 mg, 77 μmol) in DCM (2 mL). The mixture is stirred at rt for 15 h. The mixture is diluted with diethyl ether and washed with 1 N aq. HCI. The organic extract is washed with 33% aq. KOH solution, dried over MgS04, filtered and concentrated. The crude product is purified by reverse phase MPLC to give 2-benzyloxy-N-{2-chloro-4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenyl}-acetamide (12 mg) as a pale yellow oil; LC-MS: tp = 0.68 min; [M+1] = 529.18. The material is dissolved in THF:ethanol 1:1 (5 mL) and Pd/C (10 mg, 10% Pd) is added. The mixture is stirred at rt for 15 h under 5 bar of H2. The catalyst is removed by filtration and the filtrate is concentrated. The crude product is purified on prep. TLC plates with DCM containing 4% of methanol to give the title compound (4 mg) as a white solid; LC-MS: tR = 0.50 min; [M+1] = 448.98; H NMR (CD3OD): 51.13 (t, J = 7.0 Hz, 6 H), 2.29 (s, 3 H), 2.39 (s, 3 H), 2.66 (q, J = 6.8 Hz, 4 H), 3.80 (s, 2 H), 4.24 (s, 2 H), 7.75 (s, 1 H), 8.00 (s, 1 H), 8.06 (s, 1 H). Example 189 4-[5-(5-Diethylaininoinethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-N-(2- hydroxy-ethyl)-benzamide a) 4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]- benzoic acid ethyl ester (1.42 g) is prepared starting from 4-(N-hydroxycarbamimidoyl)-benzoic acid ethyl ester (1.01 g, 4.84 mmol) and 5- diethylaminomethyl-4-methyl-thiophene-2-carboxylic acid (1.00 g, 4.40 mmol) according to Method A; LC-MS: tn = 0.63 min; [M+1] = 400.12; 1H NMR (CDCI3): S 1.11 (t, J = 7.0 Hz, 6 H), 1.45 (t, J = 7.0 Hz, 3 H), 2.26 (s, 3 H), 2.64 (q, J = 7.0 Hz, 4 H), 3.73 (s, 2 H), 4.44 (q, J = 7.3 Hz, 2 H), 7.69 (s, 1 H), 8.16-8.20 (m, 2 H), 8.22-8.25 (m, 2 H). This material (1.42 g, 3.58 mmol) is dissolved in 2 M LiOH in methanol (50 mL) and the mixture is stirred at rt for 20 h before it is acidified by adding aq. HCI. The mixture is extracted twice with EA. The combined organic extracts are dried over MgS04, filtered and concentrated. The crude product is purified by prep. HPLC to give 4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid (710 mg) as a white solid; LC-MS: tp = 0.52 min; [M+1] = 372.14. b) To a soiution of 4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid (400 mg, 1.08 mmol) in DMF (5 mL), HOBt (160 mg, 1.19 mmol) foliowed by EDC HCI (227 mg, 1.19 mmol) is added. The mixture is stirred at rt for 5 min before ethanolamine (72 mg, 1.19 mmol) is added. The reaction mixture is stinred at rt for 1 h. The mixture is diluted with EA and washed with sat. aq. NaHCOa. The washing is extracted back twice with EA. The combined organic extracts are dried over MgS04, filtered and concentrated. The crude product is purified by CC on silica gel eluting with DCM containing 4% of methanol to give the title compound (290 mg) as a white solid; LC-MS: tp = 0.47 min; [M+1]* = 415.14; ^H NMR (CDCI3): ^1.11 (t, J = 7.0 Hz, 6 H), 2.26 (s, 3 H), 2.64 (q, J = 7.0 Hz, 4 H), 3.67-3.72 (m, 2 H), 3.73 (s, 2 H), 3.90 (t, J = 4.8 Hz, 2 H), 6.69 (t br, J = 5.3 Hz, 1 H), 7.68 (s, 1 H), 7.91-7.95 (m, 2 H), 8.22-8.26 (m, 2 H). Example 190 4-[5-(5-Diethylaminomethyl-4-methyi-thiophen-2-yl)-[1,2,4]oxadiazol-3-yi]-2- methoxy-6-methyl-phenol The title compound (16 mg) is prepared starting from 5-diethylaminomethyl-4-methyl-thiophene-2-carboxylic acid (30 mg, 130 μmol) and 4,N-dihydroxy-3-methoxy-5-methyl-benzamidine (23 mg, 117 μmol) according to Method A; LC-MS: tp = 0.57 min; [M+1] = 387.78. Example 191 4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2- methyl-6-propyl-phenol The title compound (20 mg) is prepared starting from 5-diethylaminomethyl-4-methyl-thiophene-2-carboxylic acid (30 mg, 130 μmol) and 4,N-dihydroxy-3-propyl-5-methyl-benzamidine (24 mg, 117 μmol) according to Method A; LC-MS: tp = 0.64 min; [M+lf = 400.22; ^H NMR (D6-DMSO): ^0.94 (t, J = 7.3 Hz, 3 H), 1.03 (t, J = 7.0 Hz, 6 H), 1.53-1.64 (m, 2 H), 2.22 (s, 3 H), 2.26 (s, 2 H), 2.57 (q, J = 7.0 Hz, 4 H), 2.61-2.66 (m, 2 H), 3.73 (s, 2 H), 7.59-7.62 (m, 1 H), 7.62-7.65 (m, 1 H), 7.78 (s, 1 H), 8.88 (s br, 1 H). Example 192 2-Chloro-4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol- 3-yl]-6-methyl-phenol The title compound (11 mg) is prepared starting from 5-diethylaminomethyl-4-methyl-thiophene-2-carboxylic acid (30 mg, 130 μmol) and 4,N-dihydroxy-3-chloro-5-methyl-benzamidine (23 mg, 117 μmol) according to Method A; LC-MS: tp = 0.60 min; [M+ir = 392.12. Example 193 4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)'-[1,2,4]oxadiazol-3-yl]-3- methoxy-phenol The title compound (7 mg) is prepared starting from 5-diethylaminomethyl-4-methyl-thiophene-2-carboxylic acid (30 mg, 130 μmol) and 4,N-dihydroxy-2-methoxy-benzamidine (21 mg, 117 μmol) according to Method A; LC-MS: = 0.50 min; [M+1] = 374.12. Example 194 N-((2S)-3-{4-[5-(5-Diethyiaminomethyl-4-methyl-thiophen-2-yi)-[1,2,4]oxadlazol-3-yl]-2-methoxy-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide The title compound (6 mg) is prepared starting from 5-diethylaminomethyl-4-methyl-thiophene-2-carboxylic acid (30 mg, 130 μmol) and (S)-2-hydroxy-N-(2-hydroxy-3- [4-(N-hydroxycarbamimidoyl)-2-methoxy-6-methyl-phenoxy]-propyl)-acetamide (38 mg, 117μmol) according to Method A; LC-MS: tR = 0.51 min; [M+1]* = 519.17. Example 195 N-((2S)-3-{4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-chloro-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hyd roxy-acetam ide The title compound (31 mg) is prepared starting from 5-diethylaminomethyl-4-methyl-thiophene-2-cart)Oxylic acid (30 mg, 130 μmoi) and (S)-2-hydroxy-N-(2-hydroxy-3-[4-(N-hydroxycarbamimidoyl)-2-chloro-6-methyl-phenoxy]-propyl)-acetamide (39 mg, 117 μmol) according to Method A; LC-MS: tR = 0.53 min; [M+1]* = 523.14; "'M NMR (D6-DMSO): S1.03 (t, J = 7.0 Hz, 6 H), 2.22 (s, 3 H), 2.40 (s, 3 H), 2.58 (q, J = 7.0 Hz, 4 H), 3.20-3.29 (m, 1 H), 3.40-3.48 (m, 1 H), 3.74 (s, 2 H), 3.83 (d, J = 5.8 Hz, 2 H), 3.86-4.01 (m, 3 H), 5.32 (d, J = 5.3 Hz, 1 H), 5.55 (t, J = 6.0 Hz, 1 H), 7.70 (t br, J = 6.0 Hz, 1 H), 7.82 (s, 1 H), 7.86-7.89 (m, 1 H), 7.89-7.90 (m, 1 H). Example 196 N-(3-{4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3- yl]-3-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide The title compound (3 mg) is prepared starting from 5-diethylaminomethyi-4-methyl-thiophene-2-carboxylic acid (30 mg, 130 μmol) and (S)-2-hydroxy-N-(2-hydroxy-3-[4-(N-hydroxycarbamimidoyl)-3-methyl-phenoxy]-propyl)-acetamide (35 mg, 117 μmol) according to Method A; LC-MS: tp = 0.50 min; [M+1]* = 489.23. Example 197 (2S)-3-{4-[5-(5-Diethylamlnomethyl-4-methyi-thiophen-2-yi)-[1,2,4]oxadiazol-3- yl]-2-methoxy-6-methyl-phenoxy}-propane-1,2-diol (R)-(5-{3-[4-(2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-3-methoxy-5-methyl-phenyl]-[1,2,4]oxadiazol-5-yl}-3-methyl-thiophen-2-ylmethyl)-diethyl-amine is prepared starting from 5-diethylaminomethyl-4-methyl-thiophene-2-carboxylic acid (30 mg, 130 μmol) and (R)-4-(2,2-dimethyl-[1,3]dioxolan-4-yimethoxy)-N-hydroxy-3-methoxy-5-methyl-benzamidine (36 mg, 117 ^mol) according to Method A. After the coupling and cyclisation step, the reaction mixture is acidified by adding 35% aq. HCI and the reaction mixture is stirred at rt for 40 min. The mixture is neutralised by adding 25% aq. NH3 solution before it is separated by prep. HPLC to give the title compound (31 mg) as a resin; LC-MS: tp = 0.52 min; [M+1] = 462.21; ^H NMR (D6-DMSO): J1.03 (t, J = 7.0 Hz, 6 H), 2.22 (s, 3 H), 2.32 (s, 3 H), 2.58 (q, J = 7.0 Hz, 4 H), 3.41-3.50 (m, 2 H), 3.73 (s, 2 H), 3.74-3.81 (m, 1 H), 3.84-3.89 (m, 1 H), 3.89 (s, 3 H), 4.03 (dd, J = 9.8, 4.3 Hz, 1 H), 4.59 (t, J = 5.8 Hz, 1 H), 4.84 (d, J = 5.3 Hz, 1 H), 7.44-7.47 (m, 1 H), 7.49-7.52 (m, 1 H), 7.81 (s, 1 H). Example 198 (2S)-3-{2-Chloro-4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol The title compound (22 mg) is prepared starting from 5-diethylaminomethyl-4-methyl-thiophene-2-carboxylic acid (30 mg, 130 μmol) and (R)-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-3-chioro-5-methyi-benzamidine (37 mg, 117 nmol) in analogy to Example 197; LC-MS: XR = 0.54 min; [M+1] = 466.05. Example 199 (2S)-3-{4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-3-methoxy-phenoxy}-propane-1,2-diol The title compound (13 mg) is prepared starting from 5-diethylaminomethyl-4-methyl-thiophene-2-carboxylic acid (30 mg, 130 μmol) and (R)-4-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-N-hydroxy-2-methoxy-benzamidine (35 mg, 117 μmol) in analogy to Example 197; LC-MS: tR = 0.47 min; [M+l]* = 448.09. Example 200 (2S)-1-Amino-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)- [1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propan-2-ol a) To a solution of 4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenol (1.49 g, 3.87 mmol) in isopropanol (70 mL) and 3 N aq. NaOH (19 mL), (R)-epichlorohydrine is added. The mixture is stirred at rt for 41 h. The mixture is diluted with EA and washed with 1 M aq. NaOH. The washing is extracted back with EA. The organic extracts are combined, dried over MgS04, filtered and concentrated. The crude product is purified by prep. HPLC (XBridge C18, 50x50 mm, 10 μm, eluting with a gradiënt of acetonitrile in water containing 0.5% of concentrated aq. ammonia) to give diethyl-{5-[3-((S)-3-ethyl-5-methyl-4-oxiranylmetlioxy-plienyl)-[1,2,4]oxadiazol-5-yl]-3-metiiyl-tiiiophen-2-ylmethyl}-amine (990 mg) as a pale yellow resin; LC-MS: tp = 0.65 min; [M+1]* = 442.09. b) A solution of diethyl-{5-[3-((S)-3-etliyl-5-methyl-4-oxiranylmetiioxy-phenyl)-[1,2,4]oxadiazol-5-yl]-3-metliyl-thioplien-2-ylmetliyl}-amine (450 mg, 1.02 mmol) in 7 N NH3 in methanol is stirred in a sealed vessel at 65°C for 16 h. The solvent is evaporated and the crude product is purified by prep. HPLC. The product containing fractions are filtered over Amberlyst A21. The filtrate is concentrated and dried to give the title compound (381 mg) as a yellow resin; LC-MS: tp = 0.44 min; [M+1] = 459.10; ^H NMR (D6-DMSO): ^1.03 (t, J = 7.0 Hz, 6 H), 1.23 (t, J = 7.5 Hz, 3 H), 2.22 (s, 3 H), 2.35 (s, 3 H), 2.58 (q, J = 7.0 Hz, 4 H), 2.73 (q, J = 7.5 Hz, 2 H), 2.88 (dd, J = 12.8, 9.0 Hz, 1 H), 3.10 (dd, J = 12.5, 3.0 Hz, 1 H), 3.73 (s, 2 H), 3.81 (d, J - 5.3 Hz, 2 H), 4.04-4.12 (m, 1 H), 7.75 (s, 2 H), 7.80 (s, 1 H). Example 201 2-{4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2- ethyl-6-methyl-phenoxy}-ethylamine To a mixture of 4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenol (700 mg, 1.82 mmol) and K2CO3 (760 mg, 5.45 mmol) in acetonitrile (14 mL), 2-(Boc-amino)-ethylbromide (839 mg, 3.63 mmol) is added. The mixture is stirred at 80°C for 12 h. The mixture is filtered and the filtrate is concentrated. The residue is dissolved in DCM (10 mL) and treated with TFA (1.4 mL). The mixture is stirred at rt for 19 h before another portion of TFA (0.7 mL) is added. Stirring is continued at rt for another 21 h. The mixture is diluted with DCM and washed with 1 M aq. NaOH. The washing is extracted back with DCM. The combined organic extracts are dried over MgS04, filtered and concentrated. The crude product is purified by prep. HPLC. The product containing fractions are combined, concentrated, dissolved in methanol:water 9:1 and filtered over Amberlyst A-21. The filtrate is evaporated and dried to give the title compound (513 mg) as a pale yellow resin; LC-MS: tp = 0.44 min; [M+lf = 429.20; ^H NMR (De-DMSO): Sim (t, J = 7.0 Hz, 6 H), 1.23 (t, J = 7.5 Hz, 3 H), 2.22 (s, 3 H), 2.35 (s, 3 H), 2.58 (q, J = 7.3 Hz, 4 H), 2.73 (q, J = 7.5 Hz, 2 H), 3.05 (t, J = 5.5 Hz, 2 H), 3.73 (s, 3 H), 3.86 (t, J = 5.5 Hz, 2 H), 7.75 (s, 2 H), 7.80 (s, 1 H). Example 202 3-{4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2- ethyl-6-methyl-phenoxy}-propylamine The title compound (309 mg) is prepared in anaiogy to Example 201 starting from 4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenol (700 mg, 1.82 mmol) and 3-(Boc-amino)-propylbromide (900 mg, 3.63 mmol); LC-MS: tp = 0.46 min; [M+1] = 443.10. Example 203 1-((2S)-3-{4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol- 3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-azetidine-3-carboxylic acid To a solution of azetidine-2-carboxylic acid methyl ester hydrochloride (51 mg, 340 μmol) in methanol (1 mL), a solution of diethyl-{5-[3-((S)-3-ethyl-5-methyl-4-oxiranylmethoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-3-methyl-thiophen-2-ylmethyl}-amine (30 mg, 68 μmol) in methanol (1 mL) foliowed by DIPEA (90 mg, 679 ^mol) is added. The mixture is stirred at 70°C for 22 h before it is cooled to rt and 3 M aq. NaOH (0.35 mL) is added. The mixture is stirred at rt for 18 h before it is separated by prep. HPLC (Waters XBridge Prep C18, 75 x 30 mm ID, 10 μm, eluting with a gradiënt of acetonitrile in water containing 0.5 % of sat. aq. ammonia) to give the title compound (29 mg) as a resin; LC-MS*: tp = 0.74 min; [M+1] = 543.09; 1H NMR (De-DMSO): J1.03 (t, J = 7.0 Hz, 6 H), 1.21 (t. J = 7.5 Hz, 3 H), 2.22 (s, 3 H), 2.33 (s, 3 H), 2.58 (q, J = 7.0 Hz, 4 H), 2.62-2.69 (m, 1 H), 2.73 (q, J = 7.3 Hz, 2 H), 3.10-3.17 (m, 1 H), 3.18-3.22 (m, 1 H), 3.22-3.28 (m, 2 H), 3.42-3.51 (m, 2 H), 3.66-3.72 (m, 1 H), 3.73 (s, 2 H), 3.74-3.80 (m, 2 H), 7.72 (s, 2 H), 7.80 (s, 1 H). Example 204 (2S)-1-((2S)-3-{4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-pyrrolidine-2-carboxylic acid The title compound (25 mg) is obtained from diethyl-{5-[3-((S)-3-ethyl-5-methyl-4-oxiranylmethoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-3-methyl-thiophen-2-ylmethyl}-amine (30 mg, 68 ^mol) and L-proline methyl ester hydrochloride (56 mg, 340 itimol) in analogy to Example 203; LC-MS*: tR = 0.82 min; [M+1] = 557.16; 1H NMR (D6-DMSO): δ.03 (t, J = 7.0 Hz, 6 H), 1.22 (t, J = 7.5 Hz, 3 H), 1.66-1.77 (m, 1 H), 1.83-2.01 (m, 2 H), 2.09-2.17 (m, 1 H), 2.22 (s, 3 H), 2.35 (s, 3 H), 2.58 (q, J = 7.0 Hz, 4 H), 2.73 (q, J = 7.5 Hz, 2 H), 2.83-2.91 (m, 1 H), 3.04 (dd, J = 12.8, 9.3 Hz, 1 H), 3.15 (dd, J = 12.5, 3.3 Hz, 1 H), 3.43-3.50 (m, 1 H), 3.55 (dd, J = 9.0, 4.3 Hz, 1 H), 3.73 (s, 2 H), 3.78 (d, J = 5.0 Hz, 2 H), 4.06-4.13 (m, 1 H), 7.74 (s, 2 H), 7.80 (s, 1 H). Example 205 1-((2S)-3-{4-[5-<5-Diethylaminomethyi-4-methyl-thiophen-2-yl)-[1,2.4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-pyrrolidine-3-carboxylic acid The title compound is prepared starting from diethyl-{5-[3-((S)-3-ethyl-5-methyl-4-oxiranylmethoxy-phenyl)-I1,2,4]oxadiazol-5-yl]-3-methyl-thiophen-2-ylmethyl}-amine (30 mg, 68 μmol) and rac-pyrrolidine-3-carboxylic acid methyl ester hydrochloride (56 mg, 340 μmol) in analogy to Example 203; LC-MS*: tp = 0.76 min; [M+1] = 557.17; ^H NMR (De-DMSO): ^1.03 (t, J = 7.0 Hz, 6 H), 1.21 (t, J = 7.5 Hz, 3 H), 1.90-1.98 (m, 2 H), 2.22 (s, 3 H), 2.34 (s, 3 H), 2.43-2.49 (m, 1 H), 2.58 (q, J = 7.0 Hz, 4 H), 2.67-2.77 (m, 5 H), 2.80-2.95 (m, 2 H), 3.73 (s, 2 H), 3.74-3.77 (m, 1 H), 3.78-3.84 (m, 2 H), 3.91-3.98 (m, 1 H), 7.72 (s, 2 H), 7.80 (s, 1 H). The following Examples (7-18 mg) are prepared in analogy to Example 200 step b) starting from diethyl-{5-I3-((S)-3-ethyl-5-methyl-4-oxiranylmethoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-3-methyl-thiophen-2-ylmethyl}-amine (20 mg, 45 μmol) and the appropriate amine (225 μmol). Example 211 1H NMR (D6-DMSO): 51.04 (t, J = 6.8 Hz, 6 H), 1.22 (t, J = 7.5 Hz, 3 H), 2.22 (s, 3 H), 2.27 (s, 3 H), 2.35 (s, 3 H), 2.41-2.48 (m, 2 H), 2.58 (q, J = 7.3 Hz, 4 H), 2.74 (q, J = 7.5 Hz, 2 H), 3.48 (q, J = 5.5 Hz, 2 H), 3.73 (s, 2 H), 3.74-3.78 (m, 1 H), 3.80-3.85 (m, 1 H), 3.91-3.98 (m, 1 H), 4.37 (t br, J = 4.5 Hz), 4.84 (d br, J = 3.3 Hz, 1 H), 7.73 (s, 2 H), 7.80 (s, 1 H). Example 214 1H NMR (D6-DMSO): δ 1.04 (t, J = 7.0 Hz, 6 H), 1.22 (t, J = 7.8 Hz, 3 H), 2.22 (s, 3 H), 2.35 (s, 3 H), 2.58 (q, J = 6.8 Hz, 4 H), 2.64-2.71 (m, 1 H), 2.73 (q, J = 7.0 Hz, 2 H), 2.79-2.87 (m, 1 H), 3.33-3.47 (m, 5 H), 3.71-3.77 (m, 3 H), 3.78-3.85 (m, 1 H), 3.86-3.94 (m, 1 H), 4.37-4.45 (m, 2 H), 5.02 (d, J = 4.8 Hz, 1 H), 7.73 (s, 2 H), 7.80 (s, 1 H). The following Examples are prepared in analogy to Example 96 starting from Example 217. 218. and 219. resoectivelv. Examples 223 and 224 The following Examples (6-13 mg) are prepared in analogy to Example 163 starting from (2S)-1-amino-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)- [1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propan-2-ol (30 mg, 65 μ mol) and the appropriate carboxylic acid (72 μ mol). Example 224 ^H NMR (De-DMSO): S^.04 (t, J= 7.0 Hz, 6 H), 1.21 (t, J= 7.5 Hz, 3 H), 2.22 (s, 9 H), 2.33 (s, 3 H), 2.58 (q, J = 7.0 Hz, 4 H), 2.72 (q, J = 7.8 Hz, 2 H), 2.88 (s, 2 H), 3.20-3.28 (m, 1 H), 3.34-3.44 (m, 1 H), 3.68-3.79 (m, 4 H), 3.92-3.99 (m, 1 H), 5.29 (d, J = 5.3 Hz, 1 H), 7.73 (s, 2 H), 7.77 (t br, J = 6.0 Hz, 1 H), 7.81 (s, 1 H). The following Examples (1-2 mg) are prepared in analogy to Example 165 starting from (2S)-1-amino-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)- [1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propan-2-ol (30 mg, 65 μ mol) and the appropriate Boc-protected amino acid (72 μ mol). Example 229 4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yi]-N-(2- dimethylamino-ethyl)-benzamide The title compound (9 mg) is prepared in analogy to Example 189 step b) starting from 4-[5-(5-diethylaminomethyl-4-methyi-thiophen-2-yi)-[1,2,4]oxadiazoi-3-yl]- benzoic acid (37 mg, 100 μmol) and N1,N1-dimethyi-ethane-1,2-diamine (10 mg, 110 lamol); LC-MS: tg = 0.42 min; [M+1] = 442.23. H NMR (CDCI3): δ1.11 (t, J = 7.0 Hz, 6 H), 2.26 (s, 3 H), 2.32 (s, 6 H), 2.58 (t, J = 6.0 Hz, 2 H), 2.64 (q, J = 7.0 Hz, 4 H), 3.55-3.62 (m, 2 H), 3.73 (s, 2 H), 6.95 (t br, J = 4.8 Hz, 1 H), 7.68 (s, 1 H), 7.92-7.96 (m, 2 H), 8.21-8.25 (m, 2 H). Example 230 {4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-ylH1,2,4]oxadiazoi-3-yl]-benzoylamino}-acetic acid ethyl ester The title compound (116 mg) is obtained as a white solid in analogy to Example 189 step b) starting from 4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid (150 mg, 403 μmoi) and glycine ethyl ester (46 mg, 443 nmol); LC-MS: tR = 0.55 min; [M+1] = 457.22; H NMR (D6-DMSO): δ1.04 (t, J = 7.0 Hz, 6 H), 1.23 (t, J = 7.3 Hz, 3 H), 2.23 (s, 3 H), 2.58 (q, J = 7.0 Hz, 4 H), 3.74 (s, 2 H), 4.04 (d, J = 5.5 Hz, 2 H), 4.15 (q, J = 7.0 Hz, 2 H), 7.83 (s, 1 H), 8.07 (d, J = 8.0 Hz, 2 H), 8.17 (d, J = 7.8 Hz, 2 H), 9.15 (t, J = 5.3 Hz, 1 H). Example 231 {4-[5-(5-Diethylaminomethyi-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-benzoylamino}-acetic acid A solution of {4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-benzoylamino}-acetic acid ethyl ester (105 mg, 230 μmol) in 2 M LiOH in methanol (10 mL) is stirred at rt for 20 h. The mixture is acidified by adding aq. HCI before it is extracted twice with EA. The aq. solution is neutralised by adding sat. aq. NaHCOa solution and concentrated. The remaining solid is suspended in methanol, filtered and the filtrate is concentrated. The remaining residue is again suspended in a small volume of methanol, filtered and the filtrate is again concentrated. The crude product is purified by CC on silica gel eluting with DCM containing 20% of methanol to give the title compound (30 mg) as a white solid; LC-MS: tR = 0.48 min; [M+l]* = 429.09; ^H NMR (D6-DMSO): 1.04{t,J = 7.0 Hz, 6 H), 2.23 (s, 3 H), 2.58 (q, J = 7.3 Hz, 4 H), 3.60 (d, J = 4.8 Hz, 2 H), 3.74 (s, 2 H), 7.84 (s, 1 H), 8.02-8.07 (m, 2 H), 8.10-8.15 (m, 2 H), 8.17 (t, J = 4.5 Hz, 1 H). Example 232: GTPyS assay to determine EC50 values GTPyS binding assays are performed in 96 well microtiter plates (Nunc, 442587) in a final volume of 200 μl, using membrane preparations of CHO cells expressing recombinant human S1P1 receptor. Assay conditions are 20 mM Hepes (Fluka, 54461), 100 mM NaCI (Fluka, 71378), 5 mM MgCIa (Fluka, 63064), 0.1% BSA (Calbiochem, 126609), 1 ΜM GDP (Sigma, G-7127), 2.5% DMSO (Fluka, 41644), 50 pM 35S-GTPyS (Amersham Biosciences, SJ1320). The pH is 7.4. Test compounds are dissolved and diluted in 100% DMSO and pre-incubated at room temperature for 30 min in 150 μl of the above assay buffer, in the absence of 35S-GTPyS. After addition of 50 μi of ^^S-GTPyS, the assay is incubated for 1 h at rt. The assay is terminated by transfer of the reaction mixture to a Multiscreen plate (Millipore, MAHFC1H60) using a cell harvester from Packard Biosciences, and the plates are washed with ice-cold 10 mM Na2HP04/NaH2P04 (70%/30%), dried, sealed at the bottom and, after addition of 25 |jl MicroScint20 (Packard Biosciences, order# 6013621), sealed on the top. Membrane-bound ^^S-GTPyS is measured with a TopCount from Packard Biosciences. EC30 is the concentration of agonist inducing 50 % of the maximal speciflc 35S-GTPyS binding. Speciflc binding is determined by subtracting non-specific binding from maximal binding. Maximal binding is the amount of cpm bound to the Multlscreen plate In the presence of 10 |JM of S1P. Non-specific binding Is the amount of binding in the absence of an agonist in the assay. EC50 values of all exempllfied compounds (with the exception of the compounds of Examples 91, 95, 155, 159-161, 163-168, 200-202, 217-219, and 231 which have not been measured) are in the range of 0.2 to 5720 nM with an average of 221 nM. Agonistic activities, determined according to the method described above, of some compounds of the present invention are displayed in Table 1. Example 233: Assessment of In vivo Efficacy The efficacy of the compounds of Formula (I) is assessed by measuring the circulating lymphocytes after oral administration of 3 to 30 mg/kg of a compound of Formula (I) to normotensive male Wistar rats. The animals are housed in climate-controlled conditions with a 12 h-light/dark cycie, and have free access to normal rat chow and drinking water. Blood is collected before and 3, 6 and 24 h after drug administration. Puil blood is subjected to hematology using Advia Hematology system (Bayer Diagnostics, Zürich, Switzerland). All data are presented as mean ± SEM. Statistical analyses are performed by analysis of variance (ANOVA) using Statistica (StatSoft) and the Student-Newman-Keuls procedure for multiple comparisons. The null hypothesis is rejected when p < 0.05. As an example, Table 2 shows the effect on lymphocyte counts 3 h after oral administration of 10 mg/kg of some compounds of the present invention to normotensive male Wistar rats as compared to a group of animals treated with vehicle only. Claim 1 A compound of the Formula (I) A represents wherein the asterisks indicate the bond that is linked to the thiophene group of Formula (I); R1a represents C1-5-alkyl, C3-5-cycloalkyl, or 2-hydroxyethyl; R1b represents hydrogen or C1-3-alkyl; or R1a and R1b, together with the nitrogen to which they are attached, form an azetidine, a pyrrolidine, a piperidine, or a morpholine ring; R2 represents hydrogen or C1-2-alkyl; R3 represents hydrogen or C1-2-alkyl; R4 represents hydrogen, C1-2-alkyl, methoxy, or halogen; R5 represents hydrogen, C1-4alkyl, or C1-4-alkoxy; R6 represents hydroxy-C1-4-alkyl, di-(hydroxy-C1-4-alkyl)-C1-4-alkyl, 2,3-dihydroxypropyl, -CH2-(CH2)n-NR61R62 -CH2-(CH2)n-NHCOR64, -CH2-(CH2)n-NHSO2R63 -CH2-CH2-COOH, -CH2-CH2-CONR61R62 1-(3-carboxy-azetidinyl)-3-propionyl, 1-(2-carboxy-pyrrolidinyl)-3-propionyl, 1-(3-carboxy-pyrrolidinyl)-3-propionyl, -CH2-CH(OH)-CH2-NR61R62 -CH2-CH(OH)-CH2-NHCOR, -CH2-CH(OH)-CH2-NHSO2R63 -CO-NHR61 hydroxy, hydroxy-C2-alkoxy, di-(hydroxy-C1- 4-alkyl)-C1-4-alkoxy, 2,3-dihydroxypropoxy, 2-hydroxy-3-methoxy-propoxy, -OCH2-(CH2)n,-NR61R62 -OCH2-(CH2)m-NHCOR61, -OCH2-(CH2)m-NHSO2R64 2-[(a2etidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-2-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid)-1-yl]-ethoxy, -OCH2-CH(OH)-CH2-NR61R62 -OCH2-CH(OH)-CH2-NHCOR64, -OCH2-CH(OH)-CH2-NHSO2R63 3-[(azetidine-3-carboxylic acid)-1 -yl]-2-hydroxypropoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid)-1 -yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid)-1-yl]-propoxy, -NR61R62, -NHCO-R, or-S02NH-R61 R61 represents hydrogen, methyl, ethyl, 2-hydroxyethyl, 2-hydroxy-1-hydroxymethyl-ethyl, 2,3-dlhydroxy-propyl, 2-C1-2-alkoxyethyl, 3-hydroxypropyl, 2-aminoethyl, 2-(C1-4-alkylamlno)ethyl, 2-(di-(C1-4-alkyl)amino)ethyl, carboxymethyl, (C1-4-alkylcarboxy)methyl, 2-carboxyethyl, or 2-(C1-4-alkylcarboxy)ethyl; R62 represents hydrogen or methyl; R63 represents methyl, ethyl, methylamino, ethylamino, or dimethylamino; R64 represents hydroxymethyl, 2-hydroxyethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, 2-aminoethyl, or 2-methylamino-ethyl; m represents the integer 1 or 2; n represents 0,1, or 2; and R7 represents hydrogen, C1-2-alkyl, or halogen; 2. A compound according to claim 1, wherein A represents or a salt of such a compound. 3. A compound according to claim 1 or 2, wherein R1a represente C4-5-alkyl, or a salt of such a compound. 4. A compound according to claim 1 or 2, wherein R1a represents C4-5-alkyl, C3-4- cycloalkyl, or 2-hydroxyethyl, and R1b represents C1-3-alkyl; or R1a and R1b, together with the nitrogen to which they are attached, form an azetidine or a pyrrolidine ring; or a salt of such a compound. 5. A compound according to claim 1 or 2, wherein R1a represents C1-4-alkyl and R1-2 represents Ci.2-alkyl, or a salt of such a compound. 6. A compound according to any one of claims 1 to 5, wherein R2 represents C1.2- alkyl, or a salt of such a compound. 7. A compound according to any one of claims 1 to 6, wherein R3 represents hydrogen, or a salt of such a compound. 8. A compound according to any one of claims 1 to 7, wherein R4 represents hydrogen, R6 represents C1-3-alkyl or methoxy, and R7 represents C1-2-alkyl or chloro, or a salt of such a compound. 9. A compound according to any one of claims 1 to 8, wherein R6 represents di- (hydroxy-C1-4-alkyl)-C1-4alkyl, 2,3-dihydroxypropyl, -CH2-(CH2)n-NHCOR64, -CH2- (CH2)n-NHSO2R63 -CH2-CH2-COOH, -CH2-CH2-CONR61R621-(3-carboxy- azeticlinyl)-3-propionyl, 1 -{2-carboxy-pyrroliclinyl)-3-propionyl, 1 -(3-carboxy-pyrroliclinyl)-3-propionyl, -CH2-CH(OH)-CH2-NR61R62 -CH2-CH(OH)-CH2-NHCOR64, -CH2-CH(OH)-CH2-NHSO2R63 -CO-NHR61 hydroxy-C2-alkoxy, di-(hydroxy-C1-4-alkyl)-C1-4-alkoxy, 2,3-clihyclroxypropoxy, 2-hydroxy-3-methoxy-propoxy, -OCH2-(CH2)m-NR61R62 -OCH2-(CH2)ni-NHCOR64, -OCH2-(CH2)m-NHSO2R63 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-2-carboxylic acid)-1-yl]-ethoxy, 2-[(pyrrolidine-3-carboxylic acid)-1-yl]-ethoxy, -OCH2-CH(OH)-CH2-NR61R62 -OCH2-CH(OH)-CH2-NHCOR, -OCH2-CH(OH)-CH2-NHS02R63 3-[(azetidine-3-carboxylic acid)-1 -yl]-2-hydroxypropoxy, 2-hydroxy-3-[(pyrrolidine-2-carboxylic acid)-1 -yl]-propoxy, 2-hydroxy-3-[(pyrrolidine-3-carboxylic acid)-1-yl]-propoxy, or -NR61R62, or a salt of such a compound. 10. A compound according to any one of claims 1 to 8, wherein R^ represents di-(hydroxy-C1-4-alkyl)-C1-4-alkoxy, 2,3-dihydroxypropoxy, -OCH2-(CH2)m-NR61 R63, -OCH2-(CH2)m-NHCOR63, -OCH2-CH(OH)-CH2-NR61R62 or -OCH2-CH(OH)-CH2-NHCOR, or a salt of such a compound. 11. A compound according to any one of claims 1 to 10, wherein R" represents hydroxymethyl or 2-hydroxyethyl, or a salt of such a compound. 12. A compound according to claim 1 selected from the group consisting of. N-(3-{4-[5-(5-dimethylaminomethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; 3-[2,6-dimethyl-4-(5-{4-methyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-phenoxy]-propane-1,2-diol; N-(3-{2,6-dimethyl-4-[5-(4-methyl-5-methylaminomethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; 2-hydroxy-N-[2-hydroxy-3-(4-{5-[5-(isopropylamino-methyl)-4-methyl-thiophen-2-yl]-[1,2,4]oxadiazol-3-yl}-2,6-dimethyl-phenoxy)-propyl]-acetamide; N-(3-{4-[5-(5-dimethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-{3-[2,6-dimethyl-4-(5-{4-methyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; 2-hydroxy-N-(2-hydroxy-3-{4-[5-(5-{[(2-hydroxy-ethyl)-methyl-amino]-methyl}-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-propyl)-acetamide; N-(3-{4-[5-(5-{[ethyl-(2-hydroxy-ethyl)-amino]-methyl}-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-(3-{2,6-dimethyl-4-[5-(4-methyl-5-pyrrolidin-1-ylmethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-(3-{2,6-dimethyl-4-[5-(4-methyl-5-piperidin-1-ylmethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; 3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenyl}-propionic acid; N-((S)-3-{4-[5-(5-dimethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-4-(5-{5-[(ethyl-methyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-6-methyl-4-(5-{4-methyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[4-(5-{5-[(butyl-methyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2-ethyl-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-4-(5-{5-[(isobutyl-methyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-4-(5-{5-[(ethyl-propyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-4-(5-{5-[(ethyl-isopropyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-I4-(5-{5-[(butyl-ethyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2-ethyl-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; 3-[4-(5-{5-[(butyl-methyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2-ethyl-6-methyl-phenyl]-propionic acid; and 3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenyl}-propionic acid; or a salt of such a compound. 13. A compound according to claim 1 selected from the group consisting of: (R)-3-{4-[5-(5-dimethylaminomethyl-4-ethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-dioi; (R)-3-I2-ethyl-4-(5-{4-ethyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-propane-1,2-diol; N-((S)-3-{4-[5-(5-dimethylaminomethyl-4-ethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-4-(5-{4-ethyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; 3-{4-[5-(5-dimethylaminomethyl-4-ethyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenyl}-propionic acid; 3-[2-ethyl-4-(5-{4-ethyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenyl]-propionic acid; N-((S)-3-{4-[5-(5-dimethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,6-dimethyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-{(S)-3-[4-(5-{5-[(butyl-methyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2,6-dimethyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; 2-hydroxy-N-{(S)-2-hyclroxy-3-[4-(5-{5-[(isobutyl-methyl-amino)-methyl]-4-methyl-thiophen-2-ylH1,2,4]oxadiazol-3-yl)-2,6-dimethyl-phenoxy]-propyl}-acetamide; N-{(S)-3-[4-(5-{5-[(ethyl-propyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2,6-dimethyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[4-(5-{5-[(ethyl-isopropyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-2,6-dinnethyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; N-{(S)-3-[2-ethyl-4-(5-{5-[(ethyl-isobutyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide; (3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenyl}-propionylamino)-acetic acid; {3-[2-ethyl-4-(5-{5-[(ethyl-propyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenyl]-propionylamino}-acetic acid; 3-{3-[2-ethyl-6-methyl-4-(5-{4-methyl-5-[(methyl-propyl-amino)-methyl]-thiophen-2-ylH1,2,4]oxadiazol-3-yl)-phenyl]-propionylamino}-propionic acid; 3-(3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenyl}-propionylamino)-propionic acid; 3-{3-[2-ethyl-4-(5-{5-[(ethyl-propyl-amino)-methyl]-4-methyl-thiophen-2-yl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenyl]-propionylamino}-propionic acid; N-((S)-3-{4-[3-(5-dimethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-5-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{4-[3-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-5-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{4-[5-(5-dimethylaminomethyl-4-methyl-thiophen-2-yl)-[1,3,4]oxadiazol-2-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxacliazol-3-yl]-2-methoxy-6-methyl-phenoxy}-2-hyclroxy-propyl)-2-hyclroxy-acetamide; N-((S)-3-{2-chloro-4-[5-(5-diethylaminomethyl-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-3-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide; (S)-3-{2-chloro-4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propane-1,2-diol; (S)-1-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-nnethyl-phenoxy}-3-(2-hydroxy-ethylannino)-propan-2-ol; 3-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-propan-1-ol; 3-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-propane-1,2-diol; 2-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-propane-1,3-diol; (S)-1-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-3-(2-methoxy-ethylamino)-propan-2-ol; (S)-1-(2-amino-ethylamino)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propan-2-ol; ((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-acetic acid; [((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-methyl-amino]-acetic acid; 3-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4loxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propylamino)-propionic acid; N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-3-hydroxy-propionamide; 2-annino-N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-acetamide; N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-methylamino-acetamide; 3-amino-N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-propionamide; and N-((S)-3-{4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-3-methylamino-propionamide; or a salt of such a compound. 14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 15. A compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 14, for use as a medicament. 16. Use of a compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the prevention or treatment of diseases or disorders associated with an activated immune system. 17. The use according to claim 16 for the prevention or treatment of diseases or disorders selected from the group consisting of rejection of transplanted organs such as kidney, liver, heart, lung, pancreas, cornea, and skin; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes including rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, thyroiditis such as Hashimoto's thyroiditis, uveo-retinitis; atopic diseases such as rhinitis, conjunctivitis, dermatitis; asthma; type I diabetes; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; solid cancers and tumor metastasis.